30 Day Trial

Anika Therapeutics Reports 4Q18 Orthobiologic Revenue of $23.8MM, -5.3% vs. 4Q17

Share:

Anika Therapeutics posts 4Q18 orthobiologic revenue of USD $23.8MM, -5.3% vs. 4Q17, with 2018 full-year orthobiologic revenue of $93.6MM, -0.2% vs. 2017.

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.